AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22863639 — intervention group
Group type: COMPARATOR
Intervention: Control (no cream or oil)
Number of subjects: 100
Study 20416525 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeSiders
Number of subjects: 75
Study 20416525 — intervention group
Group type: COMPARATOR
Intervention: K-Files
Number of subjects: 75
Study 20416525 — intervention group
Group type: COMPARATOR
Intervention: K-Reamers
Number of subjects: 75
Study 18279418 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 2435
Study 15914938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 303
Study 15914938 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 303
Study 12881822 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 60
Study 12881822 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electric nerve stimulation (TENS) therapy
Number of subjects: 60
Study 10231057 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (3.6 mM)
Number of subjects: 0
Study 8692532 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF
Number of subjects: 101
Study 8692532 — intervention group
Group type: EXPERIMENTAL
Intervention: No G-CSF (no cytopenia)
Number of subjects: 101
Study 8692532 — intervention group
Group type: COMPARATOR
Intervention: Control (no G-CSF despite insufficient leukocyte recovery)
Number of subjects: 101
Study 8692532 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 101
Study 1656181 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO treatment (3 X 80 IE/kg/week for six months)
Number of subjects: 22
Study 1656181 — intervention group
Group type: EXPERIMENTAL
Intervention: rHu‐EPO treatment
Number of subjects: 22
Study 1656181 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 22
Study 7110806 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of fenoterol by nebulizer
Number of subjects: 50
Study 7110806 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg of epinephrine followed by 0.75 mg of Sus-Phrine
Number of subjects: 50
Study 31773688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 59
Study 31773688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 59
Study 28637521 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided success at a card-sorting task
Number of subjects: 35
Study 28637521 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 26829066 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg phospholipids preparation (45 ml, 15 ml 3 times per day)
Number of subjects: 40
Study 26829066 — intervention group
Group type: COMPARATOR
Intervention: Olive oil preparation
Number of subjects: 40
Study 25129204 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) for 1 year
Number of subjects: 75
Study 25129204 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) for 1 year
Number of subjects: 75
Study 22347369 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minute massage group
Number of subjects: 125
Study 22347369 — intervention group
Group type: COMPARATOR
Intervention: Usual Care control
Number of subjects: 125
Study 20121986 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention program with a family care coordinator, a geriatrician, support groups for caregivers, and individualized services
Number of subjects: 125
Study 20121986 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 125
Study 18217220 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocational rehabilitation programs during inpatient treatment
Number of subjects: 0
Study 18217220 — intervention group
Group type: COMPARATOR
Intervention: Non-specific ergo-therapeutic treatment (Control)
Number of subjects: 0
Study 16385703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand held Doppler (HHD) examination
Number of subjects: 943
Study 16385703 — intervention group
Group type: COMPARATOR
Intervention: Duplex imaging
Number of subjects: 943
Study 12572375 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiannao Yizhi Granule
Number of subjects: 242
Study 12572375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 12572375 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 242
Study 10502218 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 77
Study 10502218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 8760776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 50 micrograms
Number of subjects: 353
Study 8760776 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 100 micrograms
Number of subjects: 353
Study 8760776 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 353
Study 8760776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 1862460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan plus doxycycline
Number of subjects: 108
Study 1862460 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin plus doxycycline
Number of subjects: 108
Study 6873140 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase‐streptodornase
Number of subjects: 40
Study 6873140 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilized crystalline trypsin
Number of subjects: 40
Study 6873140 — intervention group
Group type: COMPARATOR
Intervention: Both preparations
Number of subjects: 40
Study 30168416 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute IV infusion of levetiracetam
Number of subjects: 24
Study 30168416 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-minute IV infusion of levetiracetam
Number of subjects: 24
Study 30168416 — intervention group
Group type: COMPARATOR
Intervention: Oral tablets of levetiracetam
Number of subjects: 24
Study 30346819 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecoaching programme for 24 weeks
Number of subjects: 31
Study 30346819 — intervention group
Group type: COMPARATOR
Intervention: Usual nursing care
Number of subjects: 31
Study 27490209 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenol supplementation (GTPS) for 12 months
Number of subjects: 867
Study 27490209 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 867
Study 27490209 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenol supplementation (GTPS) after three months withdrawal
Number of subjects: 867
Study 23772698 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led rheumatology clinic (intervention group)
Number of subjects: 107
Study 23772698 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologist-led clinic (control group)
Number of subjects: 107
Study 22575569 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.0 mg/kg IV initially, then adjusted based on response)
Number of subjects: 80
Study 19635718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 124
Study 19635718 — intervention group
Group type: COMPARATOR
Intervention: Instrumented transpedicular fusion
Number of subjects: 124
Study 18309444 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (480 ml of Gatorade plus 5 grams of creatine)
Number of subjects: 42
Study 18309444 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (480 ml of Gatorade plus 35 grams of whey protein powder)
Number of subjects: 42
Study 18309444 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein/creatine (480 ml of Gatorade plus 5 grams of creatine and 35 grams of whey protein powder)
Number of subjects: 42
Study 18309444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (480 ml of Gatorade)
Number of subjects: 42
Study 16156112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 25 microg, 2 doses hourly for 23.33 hours
Number of subjects: 89
Study 16156112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg, 2 doses hourly over 23.33 hours
Number of subjects: 89
Study 16156112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS 40 microg, 6, 18, 36 and 80 doses over 1, 3, 6 and 13.33 hours
Number of subjects: 89
Study 11982795 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.4 mg/kg)
Number of subjects: 65
Study 11982795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiopental (5 mg/kg)
Number of subjects: 65
Study 9516618 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and concurrent radiation for 6 weeks with no adjuvant chemotherapy
Number of subjects: 0
Study 9516618 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel and carboplatin with hyperfractionated radiation, followed by two cycles of adjuvant paclitaxel and carboplatin
Number of subjects: 0
Study 9516618 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent weekly paclitaxel plus radiation
Number of subjects: 0
Study 9516618 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and radiation therapy
Number of subjects: 0
Study 8719668 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40
Study 8719668 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with midazolam
Number of subjects: 40
Study 2561190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole
Number of subjects: 0
Study 2561190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 69126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin combined with lincomycin
Number of subjects: 52
Study 69126 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin combined with metronidazole
Number of subjects: 52
Study 69126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 52
Study 31400517 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical exome sequencing (CES)
Number of subjects: 186
Study 31400517 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 186
Study 28389911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing education program
Number of subjects: 0
Study 28389911 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 26224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 3825
Study 26224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 3825
Study 26224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 3825
Study 26224199 — intervention group
Group type: EXPERIMENTAL
Intervention: Region
Number of subjects: 3825
Study 23024219 — intervention group
Group type: EXPERIMENTAL
Intervention: High phosphate (HP, 2000 mg/day)
Number of subjects: 30
Study 23024219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phosphate (750 mg/day)
Number of subjects: 30
Study 23024219 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals)
Number of subjects: 30
Study 23024219 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 30
Study 21610514 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide
Number of subjects: 555
Study 21610514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 19387475 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily subcutaneous ghrelin treatment
Number of subjects: 12
Study 16988792 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone 1 mg per day
Number of subjects: 13
Study 16988792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Clockwise rotation (CW)
Number of subjects: 28
Study 15497371 — intervention group
Group type: COMPARATOR
Intervention: Counterclockwise rotation (CCW)
Number of subjects: 28
Study 11479485 — intervention group
Group type: EXPERIMENTAL
Intervention: Org31540/SR90107A (0.75, 1.5, 3, 6, or 8 mg/d subcutaneously)
Number of subjects: 933
Study 11479485 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (30 mg subcutaneously every 12 hours)
Number of subjects: 933
Study 9308789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg testosterone oenanthate (TE) weekly i.m. injections
Number of subjects: 33
Study 7871362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal biting force with splint covering tooth 11
Number of subjects: 10
Study 7871362 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal biting force with splint covering teeth 13-23
Number of subjects: 10
Study 7871362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite force during successive trials with single tooth
Number of subjects: 10
Study 7871362 — intervention group
Group type: EXPERIMENTAL
Intervention: Bite force during successive trials with multiple teeth
Number of subjects: 10
Study 7871362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile sensibility of tooth 11 and its antagonists
Number of subjects: 10
Study 3063134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (6 x 50 to 6 x 100 mg daily i.v.)
Number of subjects: 84
Study 3063134 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (6 x 1 g via gastric tube or per os)
Number of subjects: 84
Study 29766842 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral antibiotic prophylaxis using either 50 mg of nitrofurantoin, 100 mg of trimethoprim, or 250 mg of cefalexin for 12 months
Number of subjects: 404
Study 29766842 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for 12 months
Number of subjects: 404
Study 29766842 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral antibiotic prophylaxis
Number of subjects: 404
Study 28404658 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal mean M-value (over time)
Number of subjects: 0
Study 28404658 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-day glycemic variability measures
Number of subjects: 0
Study 27553950 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training intervention (The Incredible Years), 6 sessions
Number of subjects: 117
Study 27553950 — intervention group
Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 117
Study 23390041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (60 mg/day eicosapentaenoic acid and 252 mg/day docosahexaenoic acid) for 3 weeks
Number of subjects: 0
Study 23390041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23390041 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study 21330557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 168
Study 21330557 — intervention group
Group type: COMPARATOR
Intervention: Transarterial lipiodol chemoembolization (TACE)
Number of subjects: 168
Study 21330557 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE followed by hepatic resection
Number of subjects: 168
Study 21330557 — intervention group
Group type: COMPARATOR
Intervention: TACE with good response but refused hepatic resection
Number of subjects: 168
Study 21330557 — intervention group
Group type: COMPARATOR
Intervention: Initial hepatic resection
Number of subjects: 168
Study 19001450 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (LAMB)
Number of subjects: 0
Study 19001450 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 0
Study 17075851 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day, 15 mg/day, 35 mg/week in Europe, 50 mg/week in North America)
Number of subjects: 2483
Study 17075851 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 2483
Study 17075851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2483
Study 15521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodised salt consumption
Number of subjects: 969
Study 15521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine level measurement
Number of subjects: 969
Study 15521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt iodine level measurement
Number of subjects: 969
Study 15521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking water iodine level measurement
Number of subjects: 969
Study 15521562 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiocyanate level measurement
Number of subjects: 969
Study 11350437 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy using a 33‐mm circular stapling device (group 2)
Number of subjects: 100
Study 11350437 — intervention group
Group type: COMPARATOR
Intervention: Conventional open haemorrhoidectomy (group 1)
Number of subjects: 100
Study 11350437 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy (group 2)
Number of subjects: 100
Study 10771879 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (100,000 IU) with measles vaccine
Number of subjects: 100
Study 10771879 — intervention group
Group type: COMPARATOR
Intervention: Placebo with measles vaccine
Number of subjects: 100
Study 7714154 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical lysis of filmy adhesions
Number of subjects: 51
Study 7714154 — intervention group
Group type: COMPARATOR
Intervention: In-vitro fertilization (IVF)
Number of subjects: 51
Study 7714154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysis of filmy adhesions by laparotomy
Number of subjects: 51
Study 7714154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysis of filmy adhesions by laparoscopy
Number of subjects: 51
Study 3296724 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepridil
Number of subjects: 24
Study 3296724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 24
Study 28669666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutriose®06 (resistant dextrin) 10 g/d for 8 weeks
Number of subjects: 55
Study 27749900 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda/RBV/TVR
Number of subjects: 838
Study 27749900 — intervention group
Group type: COMPARATOR
Intervention: Alfa/RBV/TVR
Number of subjects: 838
Study 24965504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole (75 mg and 150 mg single doses)
Number of subjects: 0
Study 24965504 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 0
Study 22341290 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch urethropexy
Number of subjects: 655
Study 22341290 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655
Study 19919904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5662
Study 19919904 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline median seizure frequency
Number of subjects: 5662
Study 19919904 — intervention group
Group type: COMPARATOR
Intervention: Placebo drift
Number of subjects: 5662
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery revascularization prior to vascular surgery
Number of subjects: 377
Study 18245121 — intervention group
Group type: COMPARATOR
Intervention: No revascularization (Control)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (as a predictor)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >70 (as a predictor)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aortic surgery (as a predictor)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina (as a predictor)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline STT abnormalities (as a predictor)
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: MI status at 2.5 years post-surgery
Number of subjects: 377
Study 18245121 — intervention group
Group type: EXPERIMENTAL
Intervention: MI in diabetic patients (as a predictor of long-term mortality)
Number of subjects: 377
Study 16175132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pliva Cyclosporine Soft Gelatin Capsules (USP Modified)
Number of subjects: 0
Study 16175132 — intervention group
Group type: COMPARATOR
Intervention: Neoral (cyclosporine soft gelatin capsules, USP Modified)
Number of subjects: 0
Study 12789824 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaserc (16 mg, 3 times daily before meal)
Number of subjects: 56
Study 12789824 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine (25 mg, 3 times daily)
Number of subjects: 56
Study 10830739 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment group
Number of subjects: 68
Study 10830739 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized treatment group
Number of subjects: 68
Study 8676806 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and blood pressure interventions
Number of subjects: 840
Study 8275622 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 300
Study 8275622 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 300
Study 3829014 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy with doxorubicin and vincristine, surgery, or radiotherapy followed by additional chemotherapy with the same drug regimen
Number of subjects: 52
Study 30336847 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 244
Study 30336847 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 244
Study 27458667 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation ventilatory feedback (ESVF)
Number of subjects: 23
Study 27458667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ESVF device attached but not activated)
Number of subjects: 23
Study 24726579 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication (olanzapine, perphenazine, quetiapine, risperidone, ziprasidone)
Number of subjects: 753
Study 22540248 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheterization
Number of subjects: 139